Daud, Amna

Publishing since 2005 (Junior)

Has published 20 publications in 5 years

Number of publications published per year by Daud, Amna. (Source : PubMed)

Distribution of publications types for Daud, Amna. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br. J. Cancer 2009;101;7
Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 2009;27;17
Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin. Cancer Res. 2009;15;7
Coté GA, Gottstein JH, Daud A, Blei AT. The role of etiology in the hyperamylasemia of acute liver failure. Am. J. Gastroenterol. 2009;104;3
Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, Teitcher J, Wolchok JD, Germino FJ, Krown SE, Coit D, Rosen N, Chapman PB. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 2008;14;24
Daud A, af Klinteberg B, Rydelius PA. Trauma, PTSD and personality: the relationship between prolonged traumatization and personality impairments. Scand J Caring Sci 2008;22;3
Milone L, Daud A, Durak E, Olivero-Rivera L, Schrope B, Inabnet WB, Davis D, Bessler M. Esophageal dilation after laparoscopic adjustable gastric banding. Surg Endosc 2008;22;6
Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, Shevde LA, Li W, Eschrich S, Daud A, Ju J, Matta J. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC medical genomics 2008;1
Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J. Clin. Oncol. 2007;25;15
Jensen EH, Lewis JM, McLoughlin JM, Alvarado MD, Daud A, Messina J, Enkemann S, Yeatman TJ, Sondak VK, Riker AI. Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma. Annals of surgical oncology 2007;14;4

[ See timeline ] [ See all publications ]

h=10

means that Daud, Amna has 10 papers cited a least 10 times - methodology

Key figures

20 pub in 5 years
4.0 publications/year
best year 2006 with 6 pub
h-index 10 with 20 pub
h-ratio : 50 %

See Timeline

Ranking

It's me !

Click here if you are
Daud, Amna.

Most frequent Journals

Clin. Cancer Res. (6x)
Surg Endosc (3x)
Med. J. Malaysia (2x)
J. Clin. Oncol. (2x)
J. Clin. Endocrinol. Metab. (1x)

Main affiliation

Department of Interdisciplinary Oncology, Cutaneous Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Stabile Research Building, Room 22043, 12902 Magnolia Drive, Tampa, FL 33612, USA.

Latest co-workers

Bessler M Bicaku E Centeno B Chiappori A Conwell IM Davis D Fishman M Homsi J Inabnet WB Korner J Lush R Marchion D Minton S Munster P Olivero-Rivera L Restuccia NL Riker AI Schrope B Simon G Sullivan D

Back to HepaTop

Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.